Back
Results - Announcements
Panacea Biotec Ltd consolidated sales up 19.68% on year in Q2FY2026
13-Aug-2026, 10:25
Panacea Biotec Ltd share price gained 3.50% to Rs 414.05 after the company's net profit witnessed a sharp fall of 320% to Rs 2.2 crore, while revenue from operations increased 19.68% to Rs 199.57 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.61%. It has improved by 0.99% over last one week and advanced by 11.20% in last one month while the market capitalization of Panacea Biotec Ltd has eased by 0.85% and 6.99% in the same period respectively. Profit before tax (PBT) of Panacea Biotec Ltd stood at Rs 3.57 crore in Q2 FY26, tumbling by 45.58% year-on-year, and plunging by 385.60% quarter-on-quarter. EBITDA came in at Rs 1 crore, tanking 120.88% YoY and rallying 7050.00% sequentially. Total expenses went up by 17.28% to Rs 201.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 74.17 crore, softening by 8.18% YoY, while employee benefits expense was at Rs 44.16 crore, slipping by 5.68% YoY. For the TTM ended FY26, revenue from operations remained flat to Rs 559.09 crore, while net profit soared by 481.33% to Rs 8.72 crore, compared to previous TTM. EBITDA plunged by 4876% to Rs 46.57 crore, and PBT collapsed by 637.16% to Rs 7.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 27.37 crore in FY26, as against Rs 3.47 crore in FY25. Panacea Biotec Ltd dropped 7.13% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 2.83% during the same period.
Panacea Biotec Ltd share price gained 3.50% to Rs 414.05 after the company's net profit witnessed a sharp fall of 320% to Rs 2.2 crore, while revenue from operations increased 19.68% to Rs 199.57 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.61%. It has improved by 0.99% over last one week and advanced by 11.20% in last one month while the market capitalization of Panacea Biotec Ltd has eased by 0.85% and 6.99% in the same period respectively. Profit before tax (PBT) of Panacea Biotec Ltd stood at Rs 3.57 crore in Q2 FY26, tumbling by 45.58% year-on-year, and plunging by 385.60% quarter-on-quarter. EBITDA came in at Rs 1 crore, tanking 120.88% YoY and rallying 7050.00% sequentially. Total expenses went up by 17.28% to Rs 201.8 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 74.17 crore, softening by 8.18% YoY, while employee benefits expense was at Rs 44.16 crore, slipping by 5.68% YoY. For the TTM ended FY26, revenue from operations remained flat to Rs 559.09 crore, while net profit soared by 481.33% to Rs 8.72 crore, compared to previous TTM. EBITDA plunged by 4876% to Rs 46.57 crore, and PBT collapsed by 637.16% to Rs 7.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 27.37 crore in FY26, as against Rs 3.47 crore in FY25. Panacea Biotec Ltd dropped 7.13% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 2.83% during the same period.